Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing

Novartis Monday presented new long-term data of Zolgensma (onasemnogene abeparvovec), the only approved one-time gene therapy for the treatment of spinal muscular atrophy or SMA, demonstrating sustained durability up to 7.5 years post-dosing.